Audentes Therapeutics (NASDAQ:BOLD) was downgraded by equities research analysts at ValuEngine from a “strong-buy” rating to a “buy” rating in a note issued to investors on Saturday, ValuEngine reports.
Several other brokerages have also recently weighed in on BOLD. Svb Leerink lifted their price objective on Audentes Therapeutics from $37.00 to $48.00 and gave the company an “outperform” rating in a report on Wednesday, April 17th. HC Wainwright lifted their price objective on Audentes Therapeutics from $44.00 to $48.00 and gave the company a “buy” rating in a report on Friday, April 26th. Citigroup cut Audentes Therapeutics from a “neutral” rating to a “sell” rating and lifted their price objective for the company from $28.00 to $32.00 in a report on Friday, April 26th. Leerink Swann reissued an “outperform” rating and set a $48.00 price target (up previously from $37.00) on shares of Audentes Therapeutics in a report on Wednesday, April 17th. Finally, BidaskClub raised Audentes Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Friday. Two analysts have rated the stock with a sell rating, three have issued a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $39.92.
Shares of NASDAQ BOLD opened at $39.36 on Friday. The firm has a market capitalization of $1.74 billion, a price-to-earnings ratio of -11.58 and a beta of 1.85. Audentes Therapeutics has a fifty-two week low of $17.95 and a fifty-two week high of $46.18.
Audentes Therapeutics (NASDAQ:BOLD) last announced its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported ($1.13) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.90) by ($0.23). During the same quarter in the previous year, the business earned ($0.74) earnings per share. Equities research analysts anticipate that Audentes Therapeutics will post -4.48 earnings per share for the current fiscal year.
In other news, Director Louis G. Lange sold 20,000 shares of the business’s stock in a transaction on Monday, March 25th. The stock was sold at an average price of $36.00, for a total transaction of $720,000.00. Following the completion of the transaction, the director now owns 306,099 shares of the company’s stock, valued at approximately $11,019,564. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, VP Suyash Prasad sold 10,000 shares of the business’s stock in a transaction on Monday, May 13th. The stock was sold at an average price of $36.98, for a total value of $369,800.00. Following the transaction, the vice president now directly owns 28,236 shares of the company’s stock, valued at approximately $1,044,167.28. The disclosure for this sale can be found here. Insiders have sold a total of 61,000 shares of company stock valued at $2,020,400 in the last three months. 5.30% of the stock is owned by insiders.
Several institutional investors have recently bought and sold shares of the company. Partner Fund Management L.P. grew its position in Audentes Therapeutics by 94.4% during the 4th quarter. Partner Fund Management L.P. now owns 3,021,259 shares of the biotechnology company’s stock worth $64,413,000 after acquiring an additional 1,467,120 shares during the last quarter. BlackRock Inc. grew its position in Audentes Therapeutics by 15.8% during the 4th quarter. BlackRock Inc. now owns 2,974,591 shares of the biotechnology company’s stock worth $63,418,000 after acquiring an additional 406,605 shares during the last quarter. Great Point Partners LLC bought a new stake in Audentes Therapeutics during the 4th quarter worth $35,346,000. Gilder Gagnon Howe & Co. LLC grew its position in Audentes Therapeutics by 913.5% during the 1st quarter. Gilder Gagnon Howe & Co. LLC now owns 1,619,831 shares of the biotechnology company’s stock worth $63,206,000 after acquiring an additional 1,459,999 shares during the last quarter. Finally, Jennison Associates LLC grew its position in Audentes Therapeutics by 31.5% during the 1st quarter. Jennison Associates LLC now owns 1,346,970 shares of the biotechnology company’s stock worth $52,559,000 after acquiring an additional 322,279 shares during the last quarter. 97.81% of the stock is owned by institutional investors.
About Audentes Therapeutics
Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.
Recommended Story: What is a blue-chip stock?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.